A survey on the institutional practices of the use of isavuconazole in onco-hematological children, on behalf of the Infectious Working Group of AIEOP.

Authors

Lorenzo Chiusaroli, Manuela Spadea, Milena La Spina, Letizia Pomponia Brescia, Maria Rosaria D'Amico, Erica Ricci, Maria Grazia Petris, Marica De Pieri, Katia Perruccio, Alessia Pancaldi, Paola Muggeo, Antonella Colombini, Federica Galaverna, Pietro Gasperini, Valeria Petroni, Elena Soncini, Simona Rinieri, Francesca Compagno, Rossella Mura, Francesco Baccelli, Angelica Barone, Maria Vittoria Micheletti, Alessandra Biffi, Daniele Donà, Simone Cesaro

Published in

European journal of pediatrics. Volume 185. Issue 10. Sep 23, 2026. Epub Sep 23, 2026.

Abstract

Isavuconazole is a broad-spectrum antifungal agent approved for the treatment of invasive fungal infections (IFIs) in adults and, recently, in pediatric patients aged 1 year and older. Use in the pediatric setting remains limited, but available data indicate generally favorable safety and efficacy. This survey describes the institutional practices of use of isavuconazole across centers belonging to the Italian Association of Pediatric Hematology and Oncology (AIEOP). A 25-item web-based questionnaire, approved by the scientific board of the Infectious Working Group, was distributed to AIEOP centers between December 2024 and January 2025. The survey covered indications (prophylaxis and treatment), formulations and dosing, therapeutic drug monitoring (TDM), drug-drug interactions, and management of adverse events. In 22/49 (45%) responding centers, isavuconazole was available as capsules in 20/22 (91%) and as an intravenous formulation in 17/22 (77%). Primary prophylaxis was reported in 2/22 (9%), while secondary prophylaxis was reported in 12/22 (55%) centers, in patients diagnosed with possible (10/22, 45%) or probable (12/22, 55%) IFIs. In cases of Aspergillus spp. infection, 4/22 (18%) centers considered isavuconazole for first-line treatment, 14/22 (64%) for salvage treatment, and 5/22 (23%) for combination treatment. In cases of mucormycosis, 4/22 (18%) considered isavuconazole for first-line treatment, 9/22 (41%) for salvage treatment, and 5/22 (23%) for combination treatment. TDM was commonly adopted but varied across centers: 7/22 (32%) performed TDM between days 5 and 7, 4/22 (18%) only after the loading dose, and 5/22 (23%) did not perform TDM.Conclusion: The results of this study show a widespread, off-label, heterogeneous use of isavuconazole in AIEOP centers. Such variability indicates the need for more standardized indications, dosages, and monitoring strategies. What is known? • Isavuconazole is approved for invasive fungal infections in adults and, recently, in children aged =1 year, with favorable safety and efficacy, although pediatric experience remains limited. • Real-world use of isavuconazole in pediatric hematology-oncology has not been systematically described. What is new? • This national AIEOP survey shows widespread but heterogeneous use of isavuconazole, mainly as secondary prophylaxis and salvage therapy, with inconsistent therapeutic drug monitoring. • Standardized indications, dosing, and monitoring strategies are needed in pediatric onco-hematology.

PMID:
42773305
Bibliographic data and abstract were imported from PubMed on 23 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.